Showing 5261-5270 of 8923 results for "".
- Cutera's TruSculpt Flex Wins 2020 Good Housekeeping Awardhttps://practicaldermatology.com/news/cuteras-trusculpt-flex-wins-2020-good-housekeeping-award/2460373/Congrats! Cutera’s truSculpt flex won a Good Housekeeping 2020 Beauty Award Winner for Ultimate Body Product. truSculpt flex is FDA-cleared for the improvement of abdominal tone, strengthening of the abdominal muscles, and development of a firmer abdomen. It is also cleared for th
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range incl
- Urgent: CMS Extends MIPS Extreme and Uncontrollable Circumstances Exception Application Until 4/30/2020https://practicaldermatology.com/news/urgent-cms-extends-mips-extreme-and-uncontrollable-circumstances-exception-application/2460369/The Centers for Medicare & Medicaid Services (CMS) re-opened the 2019 MIPS Extreme and Uncontrollable Circumstances Exception Application to individuals, groups, and virtual groups, including those who have already submitted data, due to the 2019 Novel Coronavirus (COVID-19) pandemi
- Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting System Scores FDA 510(k) clearancehttps://practicaldermatology.com/news/bimini-health-techs-dermapose-access-office-based-fat-harvesting-system-scores-fda-510k-clearance/2460368/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access sy
- AAD Survey: Most Americans Know Sun Protection Is Important, Still Don't Protect Themselveshttps://practicaldermatology.com/news/aad-survey-most-americans-know-sun-protection-is-important-but-still-dont-protect-themselves-1/2460367/Fully 76 percent of Americans agree that sun protection is an important healthy habit, yet only 41 percent report regularly protecting themselves outdoors — increasing their risk for skin cancer, according to a new survey from the American Academy of Dermatology. What’s more
- Regulations Needed to Reduce Rates of Nickel Allergic Contact Dermatitishttps://practicaldermatology.com/news/regulations-needed-to-reduce-rates-of-nickel-allergic-contact-dermatitis/2460364/The U.S. government must start regulating nickel in clothing and jewelry to reduce nickel allergic contact dermatitis reactions, according to a new American Academy of Pediatrics policy statement.
- La Fondation La Roche-Posay (North American) Awards 2020 Grant Winnershttps://practicaldermatology.com/news/la-fondation-la-roche-posay-north-american-awards-2020-grant-winners/2460363/And the five La Fondation La Roche-Posay (North America) 2020 research grant winners in the field of dermatology are… Dawn Zhang Eichenfield, MD, PhD, Chief Dermatology Resident at the University of California, San Diego. She received the first place pr
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- COVID-19 By the Numbers: April 21 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-21-edition/2460357/More than 300,000 Americans could die if all social distancing measures are abandoned, according to documents obtained by the Center for Public Inte
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit